CRS-HIPEC for Peritoneal Mesothelioma: Understanding the 69% Five-Year Survival Rate
David Foster
February 26, 2026
CRS-HIPEC (cytoreductive surgery + hyperthermic chemotherapy) achieves 69% five-year survival for eligible peritoneal mesothelioma patients. Learn candidacy, outcomes, and leading treatment centers.